Alumis says Phase 3 data show envudeucitinib delivers 54% PASI 100 response at Week 48 in psoriasis trial

PUBT · 2d ago
Alumis says Phase 3 data show envudeucitinib delivers 54% PASI 100 response at Week 48 in psoriasis trial
  • Alumis released new Phase 3 psoriasis data presented at the 26th Annual Fall Clinical Dermatology Conference.
  • Envudeucitinib delivered rapid, sustained improvements in hard-to-treat symptoms such as scalp disease, itch, and daily functioning.
  • Patients who switched from placebo or apremilast later in the program reached similar outcomes to those treated continuously.
  • The company remains on track to file a U.S. NDA for moderate-to-severe plaque psoriasis in 4Q 2026.
  • Longer-term follow-up showed a tolerability profile consistent with earlier results, with no new safety issues flagged.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610090400PRIMZONEFULLFEED9842640) on October 09, 2026, and is solely responsible for the information contained therein.